TY - JOUR
T1 - Summary from the Kidney Cancer Association's Inaugural Think Thank
T2 - Coalition for a Cure
AU - Rini, Brian
AU - Abel, E. Jason
AU - Albiges, Laurence
AU - Bex, Axel
AU - Brugarolas, James
AU - Bukowski, Ronald M.
AU - Coleman, Jonathan A.
AU - Drake, Charles G.
AU - Figlin, Robert A.
AU - Futreal, Andy
AU - Hammers, Hans
AU - Powles, Thomas
AU - Rathmell, W. Kimryn
AU - Ricketts, Christopher J.
AU - Turajlic, Samra
AU - Wood, Christopher G.
AU - Leibovich, Bradley C.
N1 - Funding Information:
A.B. reports receiving honoraria/consultant/advisory fees from Bristol Myers Squibb, Ipsen, Novartis, Pfizer, and Roche; research funding from Pfizer; and is on the adjuvant trials steering committee for AstraZeneca, Bristol Myers Squibb, and Roche. L.A. reports disclosures with the various companies: Amgen, AstraZeneca, Bristol-Myers-Squibb, Corvus Pharmaceuticals, Exelixis, Ipsen, Merck, MSD, Novartis, Peloton Therapeutics, Pfizer, and Roche. J.B. reports receiving honoraria/consultant/advisory fees from Arrowhead Pharmaceuticals and Exelixis and research funding from Arrowhead Pharmaceuticals. R.M.B. reports receiving honoraria/consultant/advisory fees from AstraZeneca, Bristol Myers Squibb, CSSi, Eisai Co, Exelixis, Janssen Pharmaceutica, Leads Biolabs, Merck & Co, NGM Biopharmaceuticals, Pfizer, Pneuma Respiratory, QED Therapeutics, and Telesta Therapeutics. C.G.D reports receiving honoraria/consultant/advisory fees from Agenus, AstraZeneca, Dendreon, Eli Lilly and Company, Genentech, Genocea Biosciences, Janssen Oncology, Laboratoires Pierre Fabre, MedImmune, and Merck & Co; and holding stock/ownership interests in Compugen, Harpoon Therapeutics, Kelo, and Tizona Therapeutics. H.H. reports receiving honoraria/consultant/advisory fees from ARMO Biosciences, Bayer, Bristol Myers Squibb, Corvus Pharmaceuticals, Eli Lilly and Company, Exelixis, Merck & Co, Novartis, Pfizer, Surface Oncology; travel/accommodation reimbursement from Bristol Myers Squibb, Eli Lilly and Company, Merck & Co, Novartis, and Pfizer; and research funding from Bristol Myers Squibb and Merck & Co. T.P. reports receiving honoraria/consultant/advisory fees from Astellas, AstraZeneca, Bristol Myers Squibb, Eisai Co, Exelixis, Incyte Corporation, Ipsen, Johnson & Johnson, Merck/MSD, Merck Serono, Novartis, Pfizer, Roche, and Seattle Genetics; travel/accommodation reimbursement from AstraZeneca, Ipsen, MSD, Pfizer, and Roche; grant funding from Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck/MSD, Merck Serono, Novartis, Pfizer, Roche, and Seattle Genetics; and is principal research investigator on projects for AstaZeneca, Eisai Co, Merck & Co, Novartis, Pfizer, and Roche/Genentech. S.T. reports receiving honoraria/consultant/advisory fees from Novartis; grant funding from Ventana Medical Systems Inc, The Rosetrees Trust, The Kidney and Melanoma Cancer Fund of the Royal Marsden Cancer Charity, Cancer Research UK, The National Institute for Health Research Biomedical Research Centre at the Royal Marsden Hospital and Institute of Cancer Research; receives speaker fees from AstraZeneca, Ipsen, and Roche; and hold patents in this space. C.G.W. reports receiving honoraria/consultant/advisory fees from the Kidney Cancer Association, Pfizer, and Physician Education Resource; and research funding from CoImmune and Mirati Therapeutics. The remaining authors have stated that they have no conflicts of interest.The authors thank the following industry and patient care representatives for their collaboration and insight during the Think Tank: Coalition for a Cure discussions: Dr. Urmi Bapat (Eisai), Dr. William Berg (Exelixis), Ms. Mahrukh Huseni (Genentech), Dr. Kala Lakshminarayanan (Merck & Co), Dr. Matthew A. Maurer (Bristol Myers Squibb), Dr. Subramanian Hariharan (Pfizer Oncology), and Dr. Rahul Tyagi (Novartis); and Kidney Cancer Research Alliance's president – Dena Battle; Kidney Cancer Action Network's president – Bryan Lewis; International Kidney Cancer Coalition's board member – Deborah Maskens, and Kidney Cancer Association's president and CEO – Gretchen Vaughan. This work was supported by the Kidney Cancer Association, a 501(c)(3) charitable organization (EIN:36-3719712). Meeting costs were additionally supported by Genentech.
Funding Information:
This work was supported by the Kidney Cancer Association , a 501(c)(3) charitable organization (EIN:36-3719712). Meeting costs were additionally supported by Genentech .
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/4
Y1 - 2021/4
N2 - Close to 74,000 cases of renal cell carcinoma (RCC) are diagnosed each year in the United States. The past 2 decades have shown great developments in surgical techniques, targeted therapy and immunotherapy agents, and longer complete response rates. However, without a global cure, there is still room for further advancement in improving patient care in this space. To address some of the gaps restricting this progress, the Kidney Cancer Association brought together a group of 27 specialists across the areas of clinical care, research, industry, and advocacy at the inaugural “Think Tank: Coalition for a Cure” session. Topics addressed included screening, imaging, rarer RCC subtypes, combination drug therapy options, and patient response. This commentary summarizes the discussion of these topics and their respective clinical challenges, along with a proposal of projects for collaboration in overcoming those needs and making a greater impact on care for patients with RCC moving forward.
AB - Close to 74,000 cases of renal cell carcinoma (RCC) are diagnosed each year in the United States. The past 2 decades have shown great developments in surgical techniques, targeted therapy and immunotherapy agents, and longer complete response rates. However, without a global cure, there is still room for further advancement in improving patient care in this space. To address some of the gaps restricting this progress, the Kidney Cancer Association brought together a group of 27 specialists across the areas of clinical care, research, industry, and advocacy at the inaugural “Think Tank: Coalition for a Cure” session. Topics addressed included screening, imaging, rarer RCC subtypes, combination drug therapy options, and patient response. This commentary summarizes the discussion of these topics and their respective clinical challenges, along with a proposal of projects for collaboration in overcoming those needs and making a greater impact on care for patients with RCC moving forward.
KW - Biomarkers
KW - Clinical needs
KW - Registry
KW - Renal cancer
KW - Renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85099505539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099505539&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2020.10.005
DO - 10.1016/j.clgc.2020.10.005
M3 - Comment/debate
C2 - 33358149
AN - SCOPUS:85099505539
SN - 1558-7673
VL - 19
SP - 167
EP - 175
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 2
ER -